Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Three vaccine candidates race to combat SARS-CoV-2

As the coronavirus disease (COVID-19) ravages across the globe, scientists are racing to develop an effective vaccine to combat the viral infection. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease has infected nearly 9 million people.

22 Jun 2020

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.

22 Jun 2020

Novel vaccine platform against COVID-19 based on engineered human mesenchymal stem cells

In a recent groundbreaking bioRxiv paper, Chinese researchers describe a novel approach towards coronavirus disease (COVID-19) vaccine design based on engineered human mesenchymal stem cells, with favorable and promising antibody response.

22 Jun 2020

Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2

A new paper from the UK vaccine research group, currently available on the bioRxiv preprint server, reveals that a single dose of ChAdOx1 nCoV-19 (AZD1222) can induce antigen-specific antibody and T cells responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a booster shot additionally enhances antibody production with an increase in neutralizing titers – particularly in pigs.

22 Jun 2020

Further confirmation Holder pasteurization inactivates SARS-CoV-2 in breast milk

Researchers in Australia have shown that a standard pasteurization method commonly used in human milk banks is effective at inactivating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

22 Jun 2020

How weather affects COVID-19 in India

With India now having endured six months of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there are now over 410,000 official cases in and more than 13,000 deaths recorded. Almost all these deaths have occurred in the last three months, April to June, with 100 deaths on April 4, 2020, increasing almost 16-fold by May 4, and 63-fold by June 4, 2020.

21 Jun 2020

Massive proteomics investigation of COVID-19 infection

Researchers from Germany and Switzerland revealed functional effects of individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins on cellular level after infection. They placed the findings into the context of host signaling pathways in order to identify vulnerable parts of the virus amenable to treatment. The study is currently available on the bioRxiv preprint server.

21 Jun 2020

A highly sensitive and specific antibody test for COVID-19

A new proof-of-concept study by UK researchers, currently available on the medRxiv* preprint server, describes the development of an enzyme-linked immunosorbent assay that can be used when lower levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific-antibodies are present in serum and saliva samples.

21 Jun 2020

Research explores the biophysical behavior of SARS-CoV-2 nucleocapsid protein

In a groundbreaking paper currently available on the bioRxiv* preprint server, the researchers from the Washington University School of Medicine and Stony Brook University showed how nucleocapsid protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is dynamic, disordered and phase separates with RNA – informing, in turn, the discovery of drugs that disrupt viral packaging.

21 Jun 2020

Interesting study on which species may be infected by SARS-CoV-2

The team from the University of Cambridge and the Pirbright Institute found that the Spike protein on SARS-CoV-2 engages with the host cell receptor angiotensin-converting enzyme 2 (ACE2) across a wide range of animals, even though the Spike binding site shows a between-species variation in its amino acid composition.

21 Jun 2020

Promising candidate monoclonal antibodies show "exquisite potency" against SAR-CoV-2

Researchers at Columbia University, Dana-Farber Cancer Institute, and the National Institutes of Health have identified and characterized a range of monoclonal antibodies that potently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

21 Jun 2020

Environmental conditions affect the stability of SARS-CoV-2, study finds

A new study led by Marshall University researcher M. Jeremiah Matson found that environmental conditions affect the stability of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human nasal mucus and sputum.

21 Jun 2020

Direct structural link between SARS-CoV-2 and essential fatty acid

Now, a new study published on the preprint server bioRxiv in June 2020 reports the discovery of a novel free fatty acid (FFA) binding pocket on the SARS-CoV-2 virus that could explain in part the viral effects of hyperinflammation, immune modulation, and membrane structure.

21 Jun 2020

Balanced B and T cell response required to control SARS-CoV-2

A new study by researchers in the Netherlands and published on the preprint server bioRxiv in June 2020 describes the differences in T and B cell responses seen in patients with severe COVID-19.

21 Jun 2020

COVID-19 plasma therapy safe and improves survival, says large study

Researchers working on COVID-19 therapy with plasma from convalescent patients have found that it is safe and effective and improves the chances of survival among those who are severely ill. The new study titled, “Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients,” is published as a preprint for the journal Mayo Clinic Proceedings.

20 Jun 2020

Italy’s sewage water shows SARS-CoV-2 present prior to reported outbreak in Wuhan

Italian researchers have found traces of the novel coronavirus SARS-CoV-2 in sewage wastewater that indicates that the virus may have been in circulation since December 2019. This controversial discovery shows that even before the first case was reported in Wuhan, China, in late December 2019, the virus had already arrived in northern Italy.

20 Jun 2020

Characterizing "re-positives" in recovered COVID-19 patients

The novel coronavirus pandemic has been spreading silently or explosively in almost every country of the world, causing almost half a million deaths and nearly 8.5 million reported cases in just six months. While much is known about the virus and the illness by now, far more remains unclear. One such is the prevalence and persistence of antiviral immunity following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

19 Jun 2020

Discovery of biomarkers that can influence COVID-19 severity

The novel coronavirus, now called the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), is the causative agent of the dreaded coronavirus disease (COVID-19). It was first discovered in Wuhan City, China, back in late December 2019 and has since then spread throughout the globe.

19 Jun 2020

Human trials to commence using SARS-CoV-2 antibodies from cow's blood

The coronavirus pandemic has sparked a sense of urgency as it actively spreads across the globe. The number of reported cases has now surpassed 8.46 million people, with a death toll of more than 453,000. Scientists and pharmaceutical companies are racing to develop an effective treatment and vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Jun 2020

Blood types and COVID-19 risk confirmed

Blood type may play a pivotal role in driving disease severity among coronavirus disease (COVID-19) patients. Genetic analysis of COVID-19 patients has shown that people with blood type O seemed to be protected against severe disease. In contrast, those with blood type A may experience complications tied to the viral infection.

18 Jun 2020